注射用紫杉醇(白蛋白结合型)在晚期非小细胞肺癌治疗中的研究进展
Research Progress in the Application of Nab-Paclitaxel in Advanced Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2021.1111755, PDF,   
作者: 李嘉欣：内蒙古民族大学第二临床学院，内蒙古 牙克石；曲洪澜*：内蒙古林业总医院，内蒙古 牙克石
关键词: 注射用紫杉醇(白蛋白结合型)；晚期非小细胞肺癌；抗肿瘤药物；Nab-Paclitaxe； Advanced Non-Small Cell Lung Cancer； Antineoplastic Drugs
摘要: 紫杉醇化疗药物在临床上应用广泛，注射用紫杉醇(白蛋白结合型) (nab-PC)是紫杉醇的一种新剂型，在2012年被美国食品和药物管理局(FDA)、2015年被欧洲批准与卡铂联合用于非小细胞肺癌(NSCLC)的治疗。这篇综述将关注注射用紫杉醇(白蛋白结合型)在晚期非小细胞肺癌中的应用进展和临床数据，为临床应用提供借鉴。
Abstract: Paclitaxel chemotherapy drugs are widely used in clinical practice. Nab-paclitaxel (nab-PC) is a novel therapeutic agent, which was approved in combination with carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC) in the United States of America by the Food and Drug Administration (FDA) in 2012 and by the European Commission in 2015. This review will focus on the development and clinical data on the use of Nab-Paclitaxel in advanced non-small cell lung cancer, and provide reference for clinical application.
文章引用：李嘉欣, 曲洪澜. 注射用紫杉醇(白蛋白结合型)在晚期非小细胞肺癌治疗中的研究进展[J]. 临床医学进展, 2021, 11(11): 5119-5123. https://doi.org/10.12677/ACM.2021.1111755

参考文献

[1] 刘宗超, 李哲轩, 张阳, 周彤, 张婧莹, 游伟程, 潘凯枫, 李文庆. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[2] 刘先芳, 梁敬钰, 孙建博. 紫杉醇: 具有里程碑意义的天然抗癌药物[J]. 世界科学技术-中医药现代化, 2017, 19(6): 941-949.
[3] Nakashima, K., Akamatsu, H., Murakami, H., et al. (2019) Carboplatin plus Nab-Paclitaxel in Performance Status 2 Patients with Advanced Non-Small-Cell Lung Cancer. Anticancer Research, 39, 1463-1468. [Google Scholar] [CrossRef] [PubMed]
[4] Untch, M., Jackisch, C., Schneeweiss, A., et al. (2016) Nab-Paclitaxel versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto-GBG 69): A Randomised, Phase 3 Trial. The Lancet Oncology, 17, 345-356. [Google Scholar] [CrossRef] 
[5] Desai, N., et al. (2006) Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel. Clinical Cancer Research, 12, 1317-1324. [Google Scholar] [CrossRef] 
[6] 候丽盈, 刘艳, 鲁鹏, 孙树, 李佩玲. 白蛋白结合型紫杉醇在宫颈癌新辅助化疗中的研究进展[J]. 国际妇产科学杂志, 2021, 48(2): 135-138+143.
[7] Socinski, M.A., et al. (2012) Weekly Nab-Paclitaxel in Combination with Carboplatin versus Solvent-Based Paclitaxel plus Carboplatin as First-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. Journal of Clinical Oncology, 30, 2055-2062. [Google Scholar] [CrossRef] 
[8] Yardley, D.A. (2013) Nab-Paclitaxel Mechanisms of Action and Delivery. Journal of Controlled Release, 170, 365-372. [Google Scholar] [CrossRef] [PubMed]
[9] 魏雅萍. 白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌的临床观察[D]: [硕士学位论文]. 北京: 北京协和医学院, 2016.
[10] 李琳, 张萍, 王晖, 等. 白蛋白结合型紫杉醇治疗复治晚期非小细胞肺癌临床观察[J]. 肿瘤研究与临床(半月刊), 2016(5): 325-327.
[11] 蒋侃, 黄诚, 吴标, 林根, 张晶. 白蛋白结合型紫杉醇单药作为三线及以上方案治疗晚期非小细胞肺癌的临床研究[J]. 分子诊断与治疗杂志, 2017, 9(2): 112-116.
[12] 陈斌. 白蛋白结合型紫杉醇二线治疗晚期非小细胞肺癌的临床效果观察[J]. 中国现代药物应用, 2020, 14(20): 4-6.
[13] Kotake, M., et al. (2020) Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Chemotherapy, 65, 21-28. [Google Scholar] [CrossRef] [PubMed]
[14] 方瑛, 王丽, 夏国豪, 史美祺. 白蛋白结合型紫杉醇联合替吉奥作为三线及以上方案治疗晚期非小细胞肺癌的临床观察[J]. 临床肿瘤学杂志, 2013, 18(12): 1131-1134.
[15] Shiroyama, T., et al. (2017) Carboplatin plus Weekly Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer Selected Based on Mini Nutritional Assessment Short-Form Scores: A Multicenter Phase 2 Study. Cancer Chemotherapy and Pharmacology, 80, 461-467. [Google Scholar] [CrossRef] [PubMed]
[16] 洪志清, 徐智文, 汪晓梅. 白蛋白结合型紫杉醇联合卡铂方案治疗老年晚期肺鳞癌的疗效及生存分析[J]. 基层医学论坛, 2021, 25(25): 3602-3603.
[17] 陈维英, 净卫娟, 辛玉珍, 杨秀丽, 刘世珍. 帕博利珠单抗联合卡铂、白蛋白紫杉醇治疗晚期非小细胞肺癌的疗效及安全性[J]. 山东医药, 2021, 61(13): 65-68.

为你推荐